Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 225 Ne Mizner Blvd, Suite 640 BOCA RATON FL 33432 |
Tel: | N/A |
Website: | www.inmunebio.com |
IR: | See website |
Key People | ||
Raymond J. Tesi President, Chief Executive Officer, Director | David J. Moss Chief Financial Officer | Mark Lowdell Chief Scientific Officer |
Business Overview |
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation. |
Financial Overview |
For the three months ended 31 March 2024, INmune Bio Inc revenues decreased 63% to $14K. Net loss increased 69% to $11M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $3.5M to $8M (expense), Other (expense) income - Balancing value decrease of 30% to $349K (income). |
Employees: | 11 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $196.09M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.13M as of Mar 31, 2024 |
EBITDA (TTM): | -$34.34M as of Mar 31, 2024 |
Net annual income (TTM): | -$34.50M as of Mar 31, 2024 |
Free cash flow (TTM): | -$18.32M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 19,782,429 as of May 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |